281 related articles for article (PubMed ID: 24974457)
1. [Research progresses of Mycobacterium tuberculosis cytochrome P450s as a potential drug target].
Lu Y; Qiao F; You XF; Yang XY
Yao Xue Xue Bao; 2014 Apr; 49(4):427-34. PubMed ID: 24974457
[TBL] [Abstract][Full Text] [Related]
2. The Mycobacterium tuberculosis cytochromes P450: physiology, biochemistry & molecular intervention.
McLean KJ; Belcher J; Driscoll MD; Fernandez CC; Le Van D; Bui S; Golovanova M; Munro AW
Future Med Chem; 2010 Aug; 2(8):1339-53. PubMed ID: 21426022
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
Hudson SA; McLean KJ; Munro AW; Abell C
Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
[TBL] [Abstract][Full Text] [Related]
4. Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.
Ortiz de Montellano PR
J Inorg Biochem; 2018 Mar; 180():235-245. PubMed ID: 29352597
[TBL] [Abstract][Full Text] [Related]
5. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes.
McLean KJ; Marshall KR; Richmond A; Hunter IS; Fowler K; Kieser T; Gurcha SS; Besra GS; Munro AW
Microbiology (Reading); 2002 Oct; 148(Pt 10):2937-2949. PubMed ID: 12368427
[TBL] [Abstract][Full Text] [Related]
6. Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?
Ortega Ugalde S; Boot M; Commandeur JNM; Jennings P; Bitter W; Vos JC
Appl Microbiol Biotechnol; 2019 May; 103(9):3597-3614. PubMed ID: 30810776
[TBL] [Abstract][Full Text] [Related]
7. Acetylene containing cyclo(L-Tyr-L-Tyr)-analogs as mechanism-based inhibitors of CYP121A1 from Mycobacterium tuberculosis.
Ortega Ugalde S; Wallraven K; Speer A; Bitter W; Grossmann TN; Commandeur JNM
Biochem Pharmacol; 2020 Jul; 177():113938. PubMed ID: 32224137
[TBL] [Abstract][Full Text] [Related]
8. Cytochromes P450: novel drug targets in the war against multidrug-resistant Mycobacterium tuberculosis.
Munro AW; McLean KJ; Marshall KR; Warman AJ; Lewis G; Roitel O; Sutcliffe MJ; Kemp CA; Modi S; Scrutton NS; Leys D
Biochem Soc Trans; 2003 Jun; 31(Pt 3):625-30. PubMed ID: 12773169
[TBL] [Abstract][Full Text] [Related]
9. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems.
McLean KJ; Dunford AJ; Neeli R; Driscoll MD; Munro AW
Arch Biochem Biophys; 2007 Aug; 464(2):228-40. PubMed ID: 17482138
[TBL] [Abstract][Full Text] [Related]
10. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
McLean KJ; Munro AW
Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1.
Kishk SM; McLean KJ; Sood S; Helal MA; Gomaa MS; Salama I; Mostafa SM; de Carvalho LPS; Munro AW; Simons C
Bioorg Med Chem; 2019 Apr; 27(8):1546-1561. PubMed ID: 30837169
[TBL] [Abstract][Full Text] [Related]
12. Structure-Function Analysis of the Essential
Padayachee T; Lamb DC; Nelson DR; Syed K
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732102
[TBL] [Abstract][Full Text] [Related]
13. Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors.
Walter I; Adam S; Gentilini MV; Kany AM; Brengel C; Thomann A; Sparwasser T; Köhnke J; Hartmann RW
ChemMedChem; 2021 Sep; 16(18):2786-2801. PubMed ID: 34010508
[TBL] [Abstract][Full Text] [Related]
14. Structural Characterization and Ligand/Inhibitor Identification Provide Functional Insights into the Mycobacterium tuberculosis Cytochrome P450 CYP126A1.
Chenge JT; Duyet LV; Swami S; McLean KJ; Kavanagh ME; Coyne AG; Rigby SE; Cheesman MR; Girvan HM; Levy CW; Rupp B; von Kries JP; Abell C; Leys D; Munro AW
J Biol Chem; 2017 Jan; 292(4):1310-1329. PubMed ID: 27932461
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.
McLean KJ; Carroll P; Lewis DG; Dunford AJ; Seward HE; Neeli R; Cheesman MR; Marsollier L; Douglas P; Smith WE; Rosenkrands I; Cole ST; Leys D; Parish T; Munro AW
J Biol Chem; 2008 Nov; 283(48):33406-16. PubMed ID: 18818197
[TBL] [Abstract][Full Text] [Related]
17. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis.
Guardiola-Diaz HM; Foster LA; Mushrush D; Vaz AD
Biochem Pharmacol; 2001 Jun; 61(12):1463-70. PubMed ID: 11377375
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Mycobacterium tuberculosis transpeptidase Ldt
de Munnik M; Lohans CT; Lang PA; Langley GW; Malla TR; Tumber A; Schofield CJ; Brem J
Chem Commun (Camb); 2019 Aug; 55(69):10214-10217. PubMed ID: 31380528
[TBL] [Abstract][Full Text] [Related]
19. Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450.
Bukhdruker S; Varaksa T; Grabovec I; Marin E; Shabunya P; Kadukova M; Grudinin S; Kavaleuski A; Gusach A; Gilep A; Borshchevskiy V; Strushkevich N
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081390
[TBL] [Abstract][Full Text] [Related]
20. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
